Clinical Research Directory
Browse clinical research sites, groups, and studies.
SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Sponsor: Sun Yat-sen University
Summary
•This is a randomized, open-label, multi-center, phases 2 and phase 3 trial to evaluate the efficacy and safety of SBRT combined with Camrelizumab and Apatinib as conversion therapy versus Camrelizumab combined with Apatinib as first-Line therapy for unresectable hepatocellular carcinoma.
Official title: •Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
398
Start Date
2025-01-01
Completion Date
2031-06-30
Last Updated
2024-12-18
Healthy Volunteers
No
Interventions
Radiation
Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
First line therapy
Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
First line therapy
Subjects receive Camrelizumab intravenously. Subjects receive Apatinib orally.
operation
If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
Locations (1)
the First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China